About me
Victoria Dohnal is currently Director, Regulatory Policy, North America at Johnson and Johnson (J&J) where she is responsible for driving US regulatory policy work related to rare diseases, patient focused drug development, cell and gene therapies, precision medicine, and PDUFA VII implementation and PDUFA VIII strategy. She also represents J&J at various Trade Associations and is the BIO Topic Lead on the ICH Cell and Gene Therapy Discussion Group. Prior to joining J&J she was on the science and regulatory team at BIO for over 11 years covering a broad scope of FDA-focused topics from nonclinical to post market. In this role she was also deeply involved in proposal development and negotiation support for PDUFA VII.
